Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

862 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer.
Wang X, Semba T, Manyam GC, Wang J, Shao S, Bertucci F, Finetti P, Krishnamurthy S, Phi LTH, Pearson T, Van Laere SJ, Burks JK, Cohen EN, Reuben JM, Yang F, Min H, Navin N, Trinh VN, Iwase T, Batra H, Shen Y, Zhang X, Tripathy D, Ueno NT. Wang X, et al. Among authors: iwase t. Sci Adv. 2022 Dec 16;8(50):eabn7983. doi: 10.1126/sciadv.abn7983. Epub 2022 Dec 16. Sci Adv. 2022. PMID: 36525493 Free PMC article.
A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment.
Lim B, Murthy RK, Lee J, Jackson SA, Iwase T, Davis DW, Willey JS, Wu J, Shen Y, Tripathy D, Alvarez R, Ibrahim NK, Brewster AM, Barcenas CH, Brown PH, Giordano SH, Moulder SL, Booser DJ, Moscow JA, Piekarz R, Valero V, Ueno NT. Lim B, et al. Among authors: iwase t. Br J Cancer. 2019 Jun;120(12):1105-1112. doi: 10.1038/s41416-019-0473-y. Epub 2019 May 17. Br J Cancer. 2019. PMID: 31097774 Free PMC article. Clinical Trial.
Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer.
Ueno NT, Tahara RK, Fujii T, Reuben JM, Gao H, Saigal B, Lucci A, Iwase T, Ibrahim NK, Damodaran S, Shen Y, Liu DD, Hortobagyi GN, Tripathy D, Lim B, Chasen BA. Ueno NT, et al. Among authors: iwase t. Cancer Med. 2020 Feb;9(3):1025-1032. doi: 10.1002/cam4.2780. Epub 2019 Dec 18. Cancer Med. 2020. PMID: 31849202 Free PMC article. Clinical Trial.
The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.
Chainitikun S, Long JP, Rodriguez-Bautista R, Iwase T, Tripathy D, Fujii T, Ueno NT. Chainitikun S, et al. Among authors: iwase t. Breast Cancer Res Treat. 2020 Oct;183(3):729-739. doi: 10.1007/s10549-020-05837-6. Epub 2020 Jul 27. Breast Cancer Res Treat. 2020. PMID: 32720114 Free PMC article.
Targeting Signaling Pathways in Inflammatory Breast Cancer.
Wang X, Semba T, Phi LTH, Chainitikun S, Iwase T, Lim B, Ueno NT. Wang X, et al. Among authors: iwase t. Cancers (Basel). 2020 Sep 1;12(9):2479. doi: 10.3390/cancers12092479. Cancers (Basel). 2020. PMID: 32883032 Free PMC article. Review.
862 results